® SIRS and Sepsis in Critical Care Medicine Post surgical Bacterial Pancreatitis Viral Trauma / Burns Fungal Others Others (According to Bone RC et al., Chest 1992) REGAIN CONTROL Your CytoSorb therapy goals: • Control the systemic inflammation • Modulate the immune response • Improve hemodynamics and fluid balance • Prevent and limit organ failure ® Stabilization of hemodynamics and organ functions • Improvement of hemodynamic stability (1) • Reduction of catecholamine need • Positive impact on capillary leak syndrome and fluid balance (2) • Prevention and limitation of inflammation induced organ failure (3, 4) Modulation of the immune response Types of immunologic response in sepsis • Effective reduction of excessive cytokine levels (1, 2) • Decreased de novo synthesis of inflammatory mediators (3, 5) hyper immune status • Controlled attenuation of the overshooting immune response (2, 6) B normal immune status Re-targeting of the cellular immune defense to the focus of infection (2, 6) hypo immune status 2 6 4 ry e ov 8 Late Deaths A) healthy individual with meningococcemia B) elderly patient with malnutrition and diverticulitis C) diabetic with chronic renal failure and pneumonia Intelligent polymer technology • Safe and easy to use whole blood perfusion • Easy to combine with routine renal replacement therapies within minutes • Stand-alone hemoperfusion setup possible • Quick and sustained reduction of excessive cytokine levels and removal of myoglobin, bilirubin and free hemoglobin (1, 7) • Use of standard anticoagulation (heparin or citrate) • Excellent hemo- and biocompatibility (fulfills ISO 10993) 20cm bloodflow Section through Hemoperfusion an adsorber Literature: Adsorber bead Internal structure Peng ZY et al. Crit Care Med. 2008 May;36(5):1573-7 Peng ZY et al. Crit Care. 2014 Jul 3;18(4):R141 Peng ZY et al. Kidney Int. 2012 Feb;81(4):363-9 Mikhova KM et al. J Thorac Cardiovasc Surg. 2013 Jan;145(1):215-24 CytoSorbents Europe GmbH Bölschestraße 116 12587 Berlin, Germany Time (Days) C rec Unique extracorporeal therapy 1. 2. 3. 4. Early Deaths Office +49 30 654 99 145 Fax +49 30 654 99 146 [email protected] 5. 6. 7. 8. Kellum JA et al. Crit Care Med. 2004 Mar;32(3):801-5 Namas RA et al. Mol Med. 2012 Dec 20;18:1366-74 Kuntsevich V. I. et al. Artif Cells Blood Substit Biotechnol 2009, 37(1):45-7 Skrupky et al. Anesthesiology 2011;115(6):1349-1362 www.cytosorb.com CytoSorb and CytoSorbents are trade marks of the CytoSorbents Corporation, USA. 95-001/2.0 © Copyright 2015, CytoSorbents Europe GmbH. All rights reserved. • A (8)